These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 32065376)

  • 41. Ginger potentiates the effects of silymarin on liver fibrosis induced by CCL4: the role of galectin-8.
    Okda TM; Abd-Alhaseeb MM; Barka K; Ragab NM
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):885-891. PubMed ID: 30720197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of alcoholic liver disease].
    Fehér J; Krisztina H
    Orv Hetil; 2003 Jun; 144(26):1305-6. PubMed ID: 12894675
    [No Abstract]   [Full Text] [Related]  

  • 43. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation.
    Song Z; Song M; Lee DY; Liu Y; Deaciuc IV; McClain CJ
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):262-8. PubMed ID: 17845508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Milk thistle and chronic liver disease.
    Hoofnagle JH
    Hepatology; 2005 Jul; 42(1):4. PubMed ID: 15962321
    [No Abstract]   [Full Text] [Related]  

  • 45. Improved in vitro and in vivo hepatoprotective effects of liposomal silymarin in alcohol-induced hepatotoxicity in Wistar rats.
    Kumar N; Rai A; Reddy ND; Shenoy RR; Mudgal J; Bansal P; Mudgal PP; Arumugam K; Udupa N; Sharma N; Rao CM
    Pharmacol Rep; 2019 Aug; 71(4):703-712. PubMed ID: 31207432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
    Aller R; Laserna C; Rojo MÁ; Mora N; García Sánchez C; Pina M; Sigüenza R; Durà M; Primo D; Izaola O; de Luis D
    Rev Esp Enferm Dig; 2018 Oct; 110(10):634-640. PubMed ID: 30032630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is silymarin hepatoprotective in alcoholic liver disease?
    Berger J; Kowdley KV
    J Clin Gastroenterol; 2003 Oct; 37(4):278-9. PubMed ID: 14506381
    [No Abstract]   [Full Text] [Related]  

  • 48. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
    Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
    Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin.
    Tung NT; Tran CS; Nguyen HA; Nguyen TD; Chi SC; Pham DV; Bui QD; Ho XH
    Int J Pharm; 2019 Jan; 555():63-76. PubMed ID: 30448315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An updated systematic review of the pharmacology of silymarin.
    Saller R; Melzer J; Reichling J; Brignoli R; Meier R
    Forsch Komplementmed; 2007 Apr; 14(2):70-80. PubMed ID: 17464157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phytotherapy and NAFLD--from goals and challenges to clinical practice.
    Milosević N; Milanović M; Abenavoli L; Milić N
    Rev Recent Clin Trials; 2014; 9(3):195-203. PubMed ID: 25514914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological observations.
    Tedesco D; Domeneghini C; Sciannimanico D; Tameni M; Steidler S; Galletti S
    J Vet Med A Physiol Pathol Clin Med; 2004 Mar; 51(2):85-9. PubMed ID: 15153078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements.
    Shalan MG; Mostafa MS; Hassouna MM; El-Nabi SE; El-Refaie A
    Toxicology; 2005 Jan; 206(1):1-15. PubMed ID: 15590105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Milk thistle: Silybum marianum.
    Pepping J
    Am J Health Syst Pharm; 1999 Jun; 56(12):1195-7. PubMed ID: 10484652
    [No Abstract]   [Full Text] [Related]  

  • 58. Patented bioavailability enhancement techniques of silymarin.
    Javed S; Kohli K; Ali M
    Recent Pat Drug Deliv Formul; 2010 Jun; 4(2):145-52. PubMed ID: 20156178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral supplementation of policosanol alleviates carbon tetrachloride-induced liver fibrosis in rats.
    Zein N; Yassin F; Makled S; Alotaibi SS; Albogami SM; Mostafa-Hedeab G; Batiha GE; Elewa YHA
    Biomed Pharmacother; 2022 Jun; 150():113020. PubMed ID: 35658249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease.
    Bechynska K; Kosek V; Fenclova M; Muchova L; Smid V; Suk J; Chalupsky K; Sticova E; Hurkova K; Hajslova J; Vitek L; Stranska M
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.